Published in Proc Natl Acad Sci U S A on December 20, 1994
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev (2007) 2.50
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proc Natl Acad Sci U S A (2013) 2.19
A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs (2006) 1.15
Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res (2009) 1.13
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proc Natl Acad Sci U S A (2007) 0.99
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A (1997) 0.97
Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists. Br J Cancer (2000) 0.92
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle (2012) 0.90
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci U S A (2002) 0.89
Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc Natl Acad Sci U S A (1996) 0.85
Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Invest New Drugs (2008) 0.77
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones. Asian J Androl (2015) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47
Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods (1985) 4.19
Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci U S A (1983) 3.09
Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res (1987) 1.53
High-affinity receptors for peptides of the bombesin family in Swiss 3T3 cells. Proc Natl Acad Sci U S A (1985) 1.43
Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res (1991) 1.07
Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int J Pept Protein Res (1991) 1.04
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res (1991) 1.03
Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res (1994) 0.97
Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer (1994) 0.97
Identification of the bombesin receptor on murine and human cells by cross-linking experiments. J Biol Chem (1987) 0.96
Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem (1989) 0.95
Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J Cancer Res Clin Oncol (1994) 0.94
Solid phase synthesis of peptides containing the CH2NH peptide bond isostere. Peptides (1987) 0.93
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. J Natl Cancer Inst (1992) 0.93
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer (1994) 0.92
Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry (1990) 0.92
Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. J Biol Chem (1988) 0.91
Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Lett (1994) 0.86
Carboxyl-terminal modification of a gastrin releasing peptide derivative generates potent antagonists. J Biol Chem (1989) 0.85
Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides (1992) 0.84
Characterization of receptors for bombesin/gastrin-releasing peptide in human and murine cells. Methods Enzymol (1989) 0.80
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun (1971) 2.67
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet (1985) 2.51
Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science (1971) 2.43
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun (1971) 2.29
Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science (1975) 2.00
Isolation and properties of porcine thyrotropin-releasing hormone. J Biol Chem (1969) 1.97
Effect of growth hormone release-inhibiting hormone on gastric secretion, mucosal blood flow, and serum gastrin. Gastroenterology (1976) 1.74
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet (1973) 1.68
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer (1997) 1.64
The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun (1969) 1.62
Hypothalamic regulatory hormones. Annu Rev Biochem (1978) 1.60
Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes (2001) 1.59
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A (1986) 1.59
Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A (2000) 1.57
Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. Proc Natl Acad Sci U S A (1980) 1.54
Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1989) 1.52
Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A (1984) 1.49
Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab (2000) 1.49
The regional distribution of somatostatin in the rat brain. Endocrinology (1975) 1.48
Activity and specificity of synthetic thyrotropin-releasing hormone in man. Biochem Biophys Res Commun (1970) 1.47
Some notes on the background of the isolation, determination of structure, synthesis, and early clinical trials of the luteinizing hormone- and follicle-stimulating hormone-releasing hormone. Am J Obstet Gynecol (1976) 1.47
Isolation and structure of somatostatin from porcine hypothalami. Biochemistry (1976) 1.46
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A (1989) 1.45
Solid phase synthesis of growth hormone-release inhibiting factor. Biochem Biophys Res Commun (1973) 1.44
Isolation and structure of hypothalamic MSH release-inhibition hormone. Biochem Biophys Res Commun (1971) 1.43
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod (1994) 1.41
Hypothalamic regulatory hormones. Science (1973) 1.41
New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res (1988) 1.41
Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man. N Engl J Med (1971) 1.40
Hypothalamic neurohormones regulating anterior pituitary function. Recent Prog Horm Res (1968) 1.36
Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A (1984) 1.35
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst (1995) 1.35
Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril (1971) 1.35
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A (1995) 1.35
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1981) 1.34
Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med (1984) 1.33
The hypothalamus and reproduction. Am J Obstet Gynecol (1972) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal (1989) 1.28
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1995) 1.27
Interaction between hypothalamic peptides in a superfused pituitary cell system. Peptides (1984) 1.27
Radioimmunoassay for GH-release inhibiting hormone. Proc Soc Exp Biol Med (1975) 1.27
Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett (1985) 1.26
Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1999) 1.25
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A (1997) 1.25
Growth hormone release inhibiting hormone in acromegaly. Br Med J (1974) 1.24
LH-RH agonists and antagonists. Int J Gynaecol Obstet (1980) 1.24
Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A (1999) 1.23
DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci I (1971) 1.23
Radioimmunoassay of somatostatin. Metabolism (1978) 1.22
Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat (1982) 1.22
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab (1993) 1.22
Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion. J Clin Invest (1976) 1.22
Clinical experience with hypothalamic releasing hormones. 1. Thyrotropin-releasing hormone. Recent Prog Horm Res (1972) 1.21
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci U S A (1999) 1.21
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci U S A (1998) 1.20
Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med (1998) 1.20
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (1994) 1.19
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A (2000) 1.19
Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol (1996) 1.18
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci U S A (1996) 1.17
Stimulation of release and synthesis of luteinizing hormone(LH) and follicle stimulating hormone(FSH) in tissue culture of rat pituitaries in response to natural and synthetic LH and FSH releasing hormone. Endocrinology (1972) 1.17
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A (1994) 1.16
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol (2000) 1.16
Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci U S A (1999) 1.16
Structure of porcine thyrotropin releasing hormone. Biochemistry (1970) 1.15
The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus. J Biol Chem (1971) 1.15
Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone. Receptor (1993) 1.15
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer (2000) 1.15
Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf) (1984) 1.15
Aspects of hypothalamic regulation of the pituitary gland. Science (1978) 1.14
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab (1999) 1.14
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat (2000) 1.13
Clinical experience with hypothalamic releasing hormones. 2. Luteinizing hormone-releasing hormone and other hypophysiotropic releasing hormones. Recent Prog Horm Res (1972) 1.13
Letter: Immunohistochemical localization of somatostatin in the rat pancreas. J Histochem Cytochem (1975) 1.12
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun (1976) 1.12
Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci U S A (1988) 1.11
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol (1992) 1.11
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer (1997) 1.11
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci U S A (1996) 1.11
Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep (1984) 1.10
Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer (1990) 1.10
Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem (1976) 1.10
Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. Endocrinology (1974) 1.10
Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod (1995) 1.09
Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1989) 1.09
sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem (1999) 1.08
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci U S A (2000) 1.07